# Efficacy and Safety of Flutiform® pMDI in Adult Patients With Mild to Moderate-severe Reversible Asthma

> **NCT00476073** · PHASE3 · COMPLETED · sponsor: **Mundipharma Research Limited** · enrollment: 228 (actual)

## Conditions studied

- Asthma Bronchiale

## Interventions

- **DRUG:** FLUTIFORM® (Formoterol fumarate / Fluticasone propionate)

## Key facts

- **NCT ID:** NCT00476073
- **Lead sponsor:** Mundipharma Research Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 228 (ACTUAL)
- **Last updated:** 2018-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00476073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00476073, "Efficacy and Safety of Flutiform® pMDI in Adult Patients With Mild to Moderate-severe Reversible Asthma". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00476073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*